Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

J Fransen, H Bernelot Moens, I Speyer, P L C M van Riel, J Fransen, H Bernelot Moens, I Speyer, P L C M van Riel

Abstract

Objective: To test the efficacy of standardised monitoring using the disease activity index DAS28 versus usual care on disease modifying antirheumatic drug (DMARD) prescription and disease activity in rheumatoid arthritis.

Methods: A 24 week cluster randomised trial. Rheumatology outpatient centres were randomised to systematic monitoring of disease activity using the DAS28 (12 centres, 205 patients) or usual care (12 centres, 179 patients). The aim for the DAS group was to reach a DAS28 score of < or =3.2 by changes in DMARD treatment, at the discretion of the rheumatologist and the patient.

Results: At baseline, disease activity was the same in both groups, with an overall mean (SD) DAS28 of 4.5 (1.2); 13% of the patients had a DAS28 of < or =3.2. At 24 weeks, 31% of patients in the DAS group had a DAS28 < or =3.2, while in the usual care centres this was 16% (p = 0.028). DMARDs were changed on average in 18% of visits in the DAS centres; in the 12 usual care centres they were changed on 8% of the visits (p = 0.013). The doses of methotrexate, sulfasalazine, and corticosteroids appeared to be higher in the DAS centres than in the usual care centres, but the differences were not significant.

Conclusions: In daily practice, systematic monitoring of disease activity in rheumatoid arthritis may lead to more changes in DMARD treatment, resulting in a larger number of patients with low disease activity.

Figures

Figure 1
Figure 1
In the disease activity score (DAS) group, more patients reached low disease activity (DAS28 ⩽3.2) than in the usual care (UC) group (p = 0.028).
Figure 2
Figure 2
In the disease activity score (DAS) group, more changes in disease modifying antirheumatic drug (DMARD) treatment occurred during the course of the study (p = 0.013).
Figure 3
Figure 3
Mean dose of methotrexate (A), sulfasalazine (B), and oral prednisone (C) during the course of the study.

References

    1. Rheumatology (Oxford). 2002 Jun;41(6):601-4
    1. Fam Pract. 2000 Feb;17 Suppl 1:S17-20
    1. J Rheumatol. 2001 Jun;28(6):1431-52
    1. Ann Rheum Dis. 2001 Sep;60(9):841-5
    1. Arthritis Rheum. 2001 Sep;44(9):2009-17
    1. J Rheumatol. 2001 Jun;28(6):1413-22
    1. Arthritis Rheum. 1998 Oct;41(10):1845-50
    1. Ann Rheum Dis. 2003 Jul;62(7):624-9
    1. Arthritis Rheum. 2004 Feb 15;51(1):124-7
    1. Arthritis Rheum. 2004 Jul;50(7):2082-93
    1. Lancet. 2004 Jul 17-23;364(9430):263-9
    1. Ann Rheum Dis. 2004 Oct;63(10):1222-6

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere